Towards Personalization in the Curative Treatment of Gastric Cancer

Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different w...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 614907
Main Authors Slagter, Astrid E, Vollebergh, Marieke A, Jansen, Edwin P M, van Sandick, Johanna W, Cats, Annemieke, van Grieken, Nicole C T, Verheij, Marcel
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy. Although gastric cancer is a heterogeneous disease with respect to patient-, tumor-, and molecular characteristics, the current standard of care is still according to a one-size-fits-all approach. In this review, we discuss the background of the different treatment strategies in resectable gastric cancer including the current standard, the specific role of radiotherapy, and describe the current areas of research and potential strategies for personalization of therapy.
Bibliography:This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology
Reviewed by: Yee Ung, Sunnybrook Health Sciences Centre, Canada; Berardino De Bari, Hôpital Neuchâtelois, Switzerland
Edited by: Francesco Cellini, Catholic University of the Sacred Heart, Italy
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.614907